PLoS ONE (Jan 2020)

Development and validation of Malaysia Medication Adherence Assessment Tool (MyMAAT) for diabetic patients.

  • Ernieda Hatah,
  • Nadiah Rahim,
  • Mohd Makmor-Bakry,
  • Noraida Mohamed Shah,
  • Noraini Mohamad,
  • Mahadir Ahmad,
  • Nor Hasni Haron,
  • Choe Sze Hwe,
  • Angeline Tan Meng Wah,
  • Fahmi Hassan,
  • Shakirin Shaik Rahmat,
  • Sarah Ann Robert,
  • Noraidatulakma Abdullah

DOI
https://doi.org/10.1371/journal.pone.0241909
Journal volume & issue
Vol. 15, no. 11
p. e0241909

Abstract

Read online

Medication non-adherence remains a significant barrier in achieving better health outcomes for patients with chronic diseases. Previous self-reported medication adherence tools were not developed in the context of the Malaysia population. The most commonly used tool, MMAS-8, is no longer economical because it requires a license and currently every form used is charged. Hence, there is a need to develop and validate a new medication adherence tool. The Malaysia Medication Adherence Assessment Tool (MyMAAT) was developed by a multidisciplinary team with expertise in medication adherence and health literacy. The face and content validities of the MyMAAT was established by a panel of experts. A total of 495 patients with type 2 diabetes were recruited from the Ministry of Health facilities consisting of five hospitals and five primary health clinics. A test-retest was conducted on 42 of the patients one week following their first data collection. Exploratory factor analysis was performed to evaluate the validity of the MyMAAT. The final item for MyMAAT was compared with SEAMS, HbA1c%, Medication Possession ratio (MPR) score, and pharmacist's subjective assessment for its hypothesis testing validity. The MyMAAT-12 achieved acceptable internal consistency (Cronbach's alpha = 0.910) and stable reliability as the test-retest score showed good to excellent correlation (Spearman's rho = 0.96, p = 0.001). The MyMAAT has significant moderate association with SEAMS (Spearman's rho = 0.44, p = < 0.001) and significant relationship with HbA1c (< 8% and ≥ 8%) (χ2(1) = 13.4, p < 0.001), MPR (χ2(1) = 13.6, p < 0.001) and pharmacist's subjective assessment categories (χ2(1) = 31, p < 0.001). The sensitivity of MyMAAT-12, tested against HbA1c% was 72.9% while its specificity was 43%. This study demonstrates that the MyMAAT-12 together with other methods of assessment may make a better screening tool to identify patients who were non-adherence to their medications.